Literature DB >> 27307507

Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC.

Seble G Kassaye1, Zehava Grossman2,3, Maya Balamane1, Betsy Johnston-White4, Chenglong Liu1, Princy Kumar1, Mary Young1, Michael C Sneller5, Irini Sereti5, Robin Dewar6, Catherine Rehm5, William Meyer7, Robert Shafer4, David Katzenstein4, Frank Maldarelli3.   

Abstract

BACKGROUND: Washington, DC, has 2.5% human immunodeficiency virus (HIV) prevalence, 3.9% among African Americans. Antiretrovirals (ARTs) are the cornerstone for treatment and prevention. Monitoring changes in transmitted drug resistance (TDR) is critical for effective HIV care.
METHODS: HIV genotype data for individuals enrolled in research studies in metropolitan Washington, D.C., were used to identify TDR using the World Health Organization mutation list [Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PloS One 2009; 4:e4724]. HIV phylogenies were reconstructed using maximum likelihood and Bayesian methods. HIV transmission clusters were supported by 1000 bootstrap values >0.70 and posterior probability >0.95 of having a common ancestor.
RESULTS: Among 710 individuals enrolled in 1994-2013, the median age was 38.6 years, 46.2% were female, and 53.3% were African-American. TDR was 22.5% among 566 treatment-naive individuals; 15.8% had nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, 9.8% had nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, and 4.2% had protease inhibitor (PI) resistance. Single class TDR was 10.0%, 5.1%, and 1.6% to NRTIs, NNRTIs, and PIs. Dual TDR to PI and NRTI was seen in 1.6%, NRTI and NNRTI in 3.4%, and triple class TDR in 0.9%. TDR frequency decreased from 1994-2006 (27.1%) to 2007-2013 (19.4%; P = .02). Only 6/79 (7.6%) individuals within transmission clusters had evidence of TDR. DISCUSSIONS: We identified high prevalence of TDR among HIV-infected individuals in metropolitan Washington, DC, regardless of gender. Active surveillance for TDR is needed to guide ART usage and analyses of risk group contributions to HIV transmission and resistance.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  HIV; HIV clusters; transmission dynamics; transmitted drug resistance; women

Mesh:

Substances:

Year:  2016        PMID: 27307507      PMCID: PMC4996138          DOI: 10.1093/cid/ciw382

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

Review 1.  Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis.

Authors:  Quang D Pham; David P Wilson; Matthew G Law; Anthony D Kelleher; Lei Zhang
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

2.  A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences.

Authors:  A C Siepel; A L Halpern; C Macken; B T Korber
Journal:  AIDS Res Hum Retroviruses       Date:  1995-11       Impact factor: 2.205

3.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

Authors:  Pierre Frange; Lambert Assoumou; Diane Descamps; Antoine Chéret; Cécile Goujard; Laurent Tran; Marine Gousset; Veronique Avettand-Fenoël; Laurence Bocket; Samira Fafi-Kremer; Jerome Guinard; Laurence Morand-Joubert; Florence Nicot; Jean-Christophe Plantier; Sylvie Rogez; Marc Wirden; Christine Rouzioux; Laurence Meyer; Marie-Laure Chaix
Journal:  J Antimicrob Chemother       Date:  2015-02-26       Impact factor: 5.790

5.  Men who have sex with men, risk behavior, and HIV infection: integrative analysis of clinical, epidemiological, and laboratory databases.

Authors:  Itzchak Levy; Zohar Mor; Emilia Anis; Shlomo Maayan; Eyal Leshem; Shimon Pollack; Michal Chowers; Orna Mor; Klaris Riesenberg; Zev Sthoeger; Daniela Ram; Zehava Grossman
Journal:  Clin Infect Dis       Date:  2011-06       Impact factor: 9.079

6.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

7.  A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.

Authors:  M A Winters; K L Coolley; Y A Girard; D J Levee; H Hamdan; R W Shafer; D A Katzenstein; T C Merigan
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

8.  Persistence of HIV-1 transmitted drug resistance mutations.

Authors:  Hannah Castro; Deenan Pillay; Patricia Cane; David Asboe; Valentina Cambiano; Andrew Phillips; David T Dunn
Journal:  J Infect Dis       Date:  2013-07-31       Impact factor: 5.226

9.  Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012).

Authors:  Juan Ambrosioni; Omar Sued; David Nicolas; Marta Parera; María López-Diéguez; Anabel Romero; Fernando Agüero; María Ángeles Marcos; Christian Manzardo; Laura Zamora; Manuel Gómez-Carrillo; José María Gatell; Tomás Pumarola; José María Miró
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

10.  Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Authors:  Soo-Yon Rhee; Jose Luis Blanco; Michael R Jordan; Jonathan Taylor; Philippe Lemey; Vici Varghese; Raph L Hamers; Silvia Bertagnolio; Tobias F Rinke de Wit; Avelin F Aghokeng; Jan Albert; Radko Avi; Santiago Avila-Rios; Pascal O Bessong; James I Brooks; Charles A B Boucher; Zabrina L Brumme; Michael P Busch; Hermann Bussmann; Marie-Laure Chaix; Bum Sik Chin; Toni T D'Aquin; Cillian F De Gascun; Anne Derache; Diane Descamps; Alaka K Deshpande; Cyrille F Djoko; Susan H Eshleman; Herve Fleury; Pierre Frange; Seiichiro Fujisaki; P Richard Harrigan; Junko Hattori; Africa Holguin; Gillian M Hunt; Hiroshi Ichimura; Pontiano Kaleebu; David Katzenstein; Sasisopin Kiertiburanakul; Jerome H Kim; Sung Soon Kim; Yanpeng Li; Irja Lutsar; Lynn Morris; Nicaise Ndembi; Kee Peng Ng; Ramesh S Paranjape; Martine Peeters; Mario Poljak; Matt A Price; Manon L Ragonnet-Cronin; Gustavo Reyes-Terán; Morgane Rolland; Sunee Sirivichayakul; Davey M Smith; Marcelo A Soares; Vincent V Soriano; Deogratius Ssemwanga; Maja Stanojevic; Mariane A Stefani; Wataru Sugiura; Somnuek Sungkanuparph; Amilcar Tanuri; Kok Keng Tee; Hong-Ha M Truong; David A M C van de Vijver; Nicole Vidal; Chunfu Yang; Rongge Yang; Gonzalo Yebra; John P A Ioannidis; Anne-Mieke Vandamme; Robert W Shafer
Journal:  PLoS Med       Date:  2015-04-07       Impact factor: 11.069

View more
  19 in total

Review 1.  Decoding HIV resistance: from genotype to therapy.

Authors:  Irene T Weber; Robert W Harrison
Journal:  Future Med Chem       Date:  2017-08-09       Impact factor: 3.808

2.  Mechanism of Anti-rotavirus Synergistic Activity by Epigallocatechin Gallate and a Proanthocyanidin-Containing Nutraceutical.

Authors:  S M Lipson; G Karalis; L Karthikeyan; F S Ozen; R E Gordon; S Ponnala; J Bao; W Samarrai; E Wolfe
Journal:  Food Environ Virol       Date:  2017-05-02       Impact factor: 2.778

3.  National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States.

Authors:  William A Werbel; Diane M Brown; Oyinkansola T Kusemiju; Brianna L Doby; Shanti M Seaman; Andrew D Redd; Yolanda Eby; Reinaldo E Fernandez; Niraj M Desai; Jernelle Miller; Gilad A Bismut; Charles S Kirby; Haley A Schmidt; William A Clarke; Michael Seisa; Christos J Petropoulos; Thomas C Quinn; Sander S Florman; Shirish Huprikar; Meenakshi M Rana; Rachel J Friedman-Moraco; Aneesh K Mehta; Peter G Stock; Jennifer C Price; Valentina Stosor; Shikha G Mehta; Alexander J Gilbert; Nahel Elias; Michele I Morris; Sapna A Mehta; Catherine B Small; Ghady Haidar; Maricar Malinis; Jennifer S Husson; Marcus R Pereira; Gaurav Gupta; Jonathan Hand; Varvara A Kirchner; Avinash Agarwal; Saima Aslam; Emily A Blumberg; Cameron R Wolfe; Kevin Myer; R Patrick Wood; Nikole Neidlinger; Sara Strell; Marion Shuck; Harry Wilkins; Matthew Wadsworth; Jennifer D Motter; Jonah Odim; Dorry L Segev; Christine M Durand; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2022-06-10       Impact factor: 20.999

4.  Patterns of Transmitted Drug Resistance and Virological Response to First-line Antiretroviral Treatment Among Human Immunodeficiency Virus-Infected People Who Use Illicit Drugs in a Canadian Setting.

Authors:  M Eugenia Socías; Ekaterina Nosova; Thomas Kerr; Kanna Hayashi; P Richard Harrigan; Jeannie Shoveller; Julio Montaner; M-J Milloy
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

5.  Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort.

Authors:  Sara N Levintow; Nwora Lance Okeke; Stephane Hué; Laura Mkumba; Arti Virkud; Sonia Napravnik; Joseph Sebastian; William C Miller; Joseph J Eron; Ann M Dennis
Journal:  Open Forum Infect Dis       Date:  2018-07-20       Impact factor: 3.835

Review 6.  HIV-1 drug resistance and resistance testing.

Authors:  Dana S Clutter; Michael R Jordan; Silvia Bertagnolio; Robert W Shafer
Journal:  Infect Genet Evol       Date:  2016-08-29       Impact factor: 3.342

7.  Sociodemographic, Ecological, and Spatiotemporal Factors Associated with Human Immunodeficiency Virus Drug Resistance in Florida: A Retrospective Analysis.

Authors:  Shannan N Rich; Karalee Poschman; Hui Hu; Carla Mavian; Robert L Cook; Marco Salemi; Emma C Spencer; Mattia Prosperi
Journal:  J Infect Dis       Date:  2021-03-03       Impact factor: 5.226

8.  Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999-2014.

Authors:  Annette M Aldous; Amanda D Castel; David M Parenti
Journal:  BMC Res Notes       Date:  2017-09-11

9.  Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

Authors:  Steven J Smith; Xue Zhi Zhao; Terrence R Burke; Stephen H Hughes
Journal:  Retrovirology       Date:  2018-05-16       Impact factor: 4.602

10.  Characterization of HIV diversity, phylodynamics and drug resistance in Washington, DC.

Authors:  Marcos Pérez-Losada; Amanda D Castel; Brittany Lewis; Michael Kharfen; Charles P Cartwright; Bruce Huang; Taylor Maxwell; Alan E Greenberg; Keith A Crandall
Journal:  PLoS One       Date:  2017-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.